DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine: A multicentre retrospective study.
DNA methylation
azacitidine
hypomethylating agents
myelodysplastic syndromes
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
12 Mar 2024
12 Mar 2024
Historique:
revised:
26
02
2024
received:
21
12
2023
accepted:
27
02
2024
medline:
13
3
2024
pubmed:
13
3
2024
entrez:
12
3
2024
Statut:
aheadofprint
Résumé
Real-world data have revealed that a substantial portion of patients with myelodysplastic syndromes (MDS) does not respond to epigenetic therapy with hypomethylating agents (HMAs). The cellular and molecular reasons for this resistance to the demethylating agent and biomarkers that would be able to predict the treatment refractoriness are largely unknown. In this study, we shed light on this enigma by characterizing the epigenomic profiles of patients with MDS treated with azacitidine. Our approach provides a comprehensive view of the evolving DNA methylation architecture of the disease and holds great potential for advancing our understanding of MDS treatment responses to HMAs.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : European Regional Development Fund
ID : PID2021-125282OB-I00
Organisme : Departament de Recerca i Universitats/Generalitat de Catalunya
ID : 2021 SGR 01494
Organisme : Fundación Cellex
ID : CEL007
Informations de copyright
© 2024 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
Références
Platzbecker U, Kubasch AS, Homer-Bouthiette C, Prebet T. Current challenges and unmet medical needs in myelodysplastic syndromes. Leukemia. 2021;35(8):2182-2198.
Li H, Hu F, Gale RP, Sekeres MA, Liang Y. Myelodysplastic syndromes. Nat Rev Dis Primers. 2022;8(1):74.
Rotter LK, Shimony S, Ling K, Chen E, Shallis RM, Zeidan AM, et al. Epidemiology and pathogenesis of myelodysplastic syndrome. Cancer J. 2023;29(3):111-121.
Figueroa ME, Skrabanek L, Li Y, Jiemjit A, Fandy TE, Paietta E, et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood. 2009 Oct;114(16):3448-3458.
Moran S, Arribas C, Esteller M. Validation of a DNA methylation microarray for 850,000 CpG sites of the human genome enriched in enhancer sequences. Epigenomics. 2016;8(3):389-399.
Davalos V, Esteller M. Cancer epigenetics in clinical practice. CA Cancer J Clin. 2023;73(4):376-424.
Cocco L, Finelli C, Mongiorgi S, Clissa C, Russo D, Bosi C, et al. An increased expression of PI-PLCβ1 is associated with myeloid differentiation and a longer response to azacitidine in myelodysplastic syndromes. J Leukoc Biol. 2015;98(5):769-780.
Follo MY, Finelli C, Mongiorgi S, Clissa C, Bosi C, Testoni N, et al. Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. Proc Natl Acad Sci USA. 2009;106(39):16811-16816.
Damaraju VL, Mowles D, Yao S, Ng A, Young JD, Cass CE, et al. Role of human nucleoside transporters in the uptake and cytotoxicity of azacitidine and decitabine. Nucleosides Nucleotides Nucleic Acids. 2012;31(3):236-255.
Monika Belickova M, Merkerova MD, Votavova H, Valka J, Vesela J, Pejsova B, et al. Up-regulation of ribosomal genes is associated with a poor response to azacitidine in myelodysplasia and related neoplasms. Int J Hematol. 2016;104(5):566-573.
Iorio F, Knijnenburg TA, Vis DJ, Bignell GR, Menden MP, Schubert M, et al. A landscape of pharmacogenomic interactions in cancer. Cell. 2016;166(3):740-754.
Bonny C, Goldberg E. The CpG-rich promoter of human LDH-C is differentially methylated in expressing and nonexpressing tissues. Dev Genet. 1995;16(2):210-217.
Triozzi PL, Stirling ER, Song Q, Westwood B, Kooshki M, Forbes ME, et al. Circulating immune bioenergetic, metabolic, and genetic signatures predict melanoma Patients' response to anti-PD-1 immune checkpoint blockade. Clin Cancer Res. 2022;28(6):1192-1202.
DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617-629.
Bazinet A, Darbaniyan F, Jabbour E, Montalban-Bravo G, Ohanian M, Chien K, et al. Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study. Lancet Haematol. 2022;9(10):e756-e765.